Charles River Laboratories Intl ( (CRL) ) has released its Q2 earnings. Here is a breakdown of the information Charles River Laboratories Intl presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charles River Laboratories International, Inc. is a global provider of essential products and services that aid pharmaceutical and biotechnology companies, government agencies, and academic institutions in accelerating their research and drug development efforts.
In its second-quarter 2025 earnings report, Charles River Laboratories reported a slight increase in revenue to $1.03 billion, with GAAP earnings per share at $1.06 and non-GAAP earnings per share at $3.12. The company also updated its 2025 guidance, reflecting a more optimistic outlook based on its recent financial performance.
Key financial highlights include a 0.6% increase in overall revenue compared to the previous year, with the Discovery and Safety Assessment (DSA) segment experiencing a slight decline, while the Manufacturing Solutions and Research Models and Services segments showed growth. The GAAP operating margin decreased to 9.7% due to higher amortization expenses and restructuring costs, whereas the non-GAAP operating margin improved to 22.1% driven by better performance across all segments.
Despite challenges, the company is optimistic about the stabilization of biopharmaceutical demand and its ability to return to organic revenue growth. The management highlighted the strength of its portfolio and its leading position in the non-clinical market as key differentiators.
Looking ahead, Charles River Laboratories anticipates improved financial performance, supported by favorable demand trends and strategic initiatives. The company remains focused on leveraging its broad portfolio to capitalize on opportunities as the demand environment continues to stabilize.